Truscreen Group (TRU.NZ) Osake Kurssi

TruScreen Group Ltd develops and sells cancer detection devices and systems, focusing on cervical cancer screening. The company's AI-enabled device uses opto-electrical technology to detect precancerous and cancerous cervical changes in real-time through optical and electrical measurements of cervical tissue. The TruScreen device includes a Disposable Single Use Sensor (SUS), a Handheld Device (HHD), and an Intelligent Cradle (IC), working together to resolve issues with cytology such as failed samples, poor patient follow-up, and patient discomfort. The company also addresses challenges with HPV testing by providing an alternative solution that avoids the need for laboratory infrastructure. The primary buyers of TruScreen's products are healthcare providers and clinics specializing in women's health, particularly those seeking efficient, real-time cervical screening solutions. The technology targets segments where traditional cytology and HPV testing face limitations, such as in resource-constrained settings or where patient adherence to follow-up is low. By offering a device that eliminates the need for supporting laboratory infrastructure, TruScreen appeals to providers looking to streamline cervical cancer screening processes. TruScreen's products are designed to replace or complement existing cervical screening methods, directly addressing the shortcomings of cytology and HPV testing. The company's focus on real-time detection and ease of use positions it as a solution for healthcare systems aiming to improve early cancer detection rates while reducing patient discomfort and logistical challenges associated with current screening practices.